FOSCARNET PACKAGE INSERT PDF

Name of the medicinal product. Foscavir 24 mg/ml Solution for Infusion. 2. Qualitative and quantitative composition. Foscarnet trisodium hexahydrate 24 mg /ml. Package leaflet: Information for the user. Foscavir®. 24 mg/ml Solution for Infusion foscarnet. M UK. Read all of this leaflet carefully before you start. Foscavir™ (Foscarnet Sodium) Injection Product Insert rubber latex has not been used in the manufacture of this device or drug container closure system.

Author: Kazimi Mabei
Country: Saint Kitts and Nevis
Language: English (Spanish)
Genre: Relationship
Published (Last): 19 August 2014
Pages: 256
PDF File Size: 11.4 Mb
ePub File Size: 9.83 Mb
ISBN: 954-2-30377-775-8
Downloads: 31572
Price: Free* [*Free Regsitration Required]
Uploader: Kazrall

Treatment with clozapine has been associated with QT prolongation, TdP, cardiac arrest, and sudden death. Rare cases of QT prolongation and TdP have also been reported with ciprofloxacin during postmarketing surveillance. Ceritinib causes concentration-dependent prolongation of the QT interval. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as escitalopram.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as saquinavir. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation.

Foscavir 24 mg/ml Solution for Infusion

Major Avoid coadministration of lenvatinib with foscarnet due to the risk of QT prolongation. Moderate Foscaret for inesrt in serum creatinine and phosphorus if tenofovir is administered in combination with nephrotoxic agents, such as foscarnet.

Gemifloxacin may prolong the QT interval in some patients. The effects of this deposition on skeletal development have not been studied. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Minor When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as prochlorperazine.

  AMY GUTMANN LA IDENTIDAD EN DEMOCRACIA PDF

Prolongation of the QT interval has been reported with lenvatinib therapy. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Escitalopram has also been associated with a risk of QT prolongation and TdP. If refrigerated or exposed to temperatures below freezing point precipitation may occur.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as methadone.

Moderate The risk of renal toxicity may be increased if foscarnet is used in conjunction with other nephrotoxic agents such as penicillamine. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as eribulin.

However, diluted solutions should be refrigerated and storage restricted to 24 hours. Major Avoid coadministration of ivosidenib with foscarnet due to an increased risk of Pavkage prolongation.

Foscavir (foscarnet sodium) dose, indications, adverse effects, interactions from

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as lapatinib. Major Avoid the use of foscarnet with other drugs known to prolong the QT interval. The bone changes were characterised as increased osteoclast activity and bone resorption.

  ARROWAY STONEWORK TEXTURES VOLUME ONE PDF

Tenofovir containing products should be avoided with concurrent or recent use of a nephrotoxic agent; patients receiving concomitant nephrotoxic agents should fowcarnet carefully monitored for changes in serum creatinine and phosphorus. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as levofloxacin.

Foscavir 24 mg/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)

Ensure policies and procedures for packafe abnormalities such as tetany, seizures, and cardiac disturbances are in place prior to administering foscarnet. Induction therapy of mucocutaneous HSV infections unresponsive to aciclovir: Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin.

Ketoconazole has also been associated with prolongation of the QT interval. The physico-chemical stability ibsert foscarnet and dilutions thereof in equal parts with 0.

Recipient’s Email Separate multiple email fodcarnet with a comma Please enter valid email address Recipient’s email is required. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy.

If coadministration is necessary, monitor ECG and serum electrolytes. In clinical studies, intravitreal injection was prepared and administered as follows: Mutagenicity studies showed that foscarnet has a genotoxic potential.